CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore patent oppositions filed by Egis against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Jul 31, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 18, 2025
New UseNOVARTISJul 8, 2024
Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTISOct 9, 2023
S1P Receptor Modulators For Treating Multiple SclerosisNOVARTISJul 11, 2023
Dosing Regimen Associated With Long Acting Injectable Paliperidone EstersJANSSEN PHARMACEUTICADec 31, 2021
Therapeutic Uses Of EmpagliflozinBOEHRINGER INGELHEIMAug 12, 2019

Explore Egis's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jul 31, 2025
Patent NumberGrant DateTitleTotal Oppositions
Jan 8, 2020Compositions Comprising Amlodipine And Bisoprolol1
May 1, 2019Compositions Comrrising Amlodipine And Bisoprolol1

Top competitors of Egis

List of top competitors of Egis based on patent oppositions.